- Home
- DVLT vs CUE Comparison
DVLT vs CUE Comparison
Compare DVLT & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVLT
- CUE
- Stock Information
- Founded
- DVLT 2010
- CUE 2014
- Country
- DVLT United States
- CUE United States
- Employees
- DVLT N/A
- CUE N/A
- Industry
- DVLT
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- DVLT
- CUE Health Care
- Exchange
- DVLT NYSE
- CUE Nasdaq
- Market Cap
- DVLT 51.5M
- CUE 60.6M
- IPO Year
- DVLT N/A
- CUE 2018
- Fundamental
- Price
- DVLT $0.73
- CUE $0.84
- Analyst Decision
- DVLT
- CUE Strong Buy
- Analyst Count
- DVLT 0
- CUE 3
- Target Price
- DVLT N/A
- CUE $3.00
- AVG Volume (30 Days)
- DVLT 326.1K
- CUE 220.7K
- Earning Date
- DVLT 05-20-2025
- CUE 05-08-2025
- Dividend Yield
- DVLT N/A
- CUE N/A
- EPS Growth
- DVLT N/A
- CUE N/A
- EPS
- DVLT N/A
- CUE N/A
- Revenue
- DVLT $2,674,000.00
- CUE $9,287,000.00
- Revenue This Year
- DVLT $434.03
- CUE N/A
- Revenue Next Year
- DVLT $185.71
- CUE $4.77
- P/E Ratio
- DVLT N/A
- CUE N/A
- Revenue Growth
- DVLT 28.37
- CUE 69.16
- 52 Week Low
- DVLT $0.60
- CUE $0.45
- 52 Week High
- DVLT $7.35
- CUE $2.26
- Technical
- Relative Strength Index (RSI)
- DVLT N/A
- CUE 48.41
- Support Level
- DVLT N/A
- CUE $0.74
- Resistance Level
- DVLT N/A
- CUE $0.80
- Average True Range (ATR)
- DVLT 0.00
- CUE 0.09
- MACD
- DVLT 0.00
- CUE 0.02
- Stochastic Oscillator
- DVLT 0.00
- CUE 83.49
About DVLT DATAVAULT AI INC
Datavault AI Inc is a data technology and licensing company that enables clients and strategic partners to monetize their Blockchain Data and AI Web 3.0 assets via tokenization, data ownership and digital twins offering two solutions: Data Science licenses High-Performance Computing (HPC) software applications and Web 3.0 data management serving the biotech, energy, education, fintech, real estate, and healthcare industries, among others. Acoustic Science licenses spatial and multichannel HD sound transmission, including proprietary brands ADIO, WiSA and Sumerian, to customers in sports & entertainment, events & venues, restaurants, automotive, finance, and other industries.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.